IL1A and stroke disorder: In particular two pro-inflammatory members of the IL-1 family of cytokines, IL-1α and IL-1β, are considered the major effectors of injury, and inhibiting their signalling with the IL-1 receptor antagonist (IL-1Ra) is protective in experimental models of stroke [1], and has shown promise as a treatment in clinical trials [2].